Cannabinoids, such as cannabidivarin (CBDV) could be a therapeutic game-changer. In fact, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “Cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs.” The company added, “CBDV has been researched for its potential anti-inflammatory, anti-convulsant and neurological effects and has been the subject of studies in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain.” That news may also be beneficial for Tilray Inc. (NASDAQ: TLRY), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV).
With autism for example, treatments for “core symptoms” are lacking, according to study found here. However, that could change. “For instance, the striatum (caudate, putamen, and nucleus accumbens) plays a central role during development and its (atypical) functional connectivity (FC) may contribute to multiple ASD symptoms. We have previously shown, in the adult autistic and neurotypical brain, the non-intoxicating cannabinoid cannabidivarin (CBDV) alters the balance of striatal 'excitatory-inhibitory' metabolites, which help regulate FC, but the effects of CBDV on (atypical) striatal FC are unknown.”
InMed Pharmaceuticals Inc. (NASDAQ: INM) Just Expanded Patent Portfolio
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing. Entitled “Cannabinoid Analogs and Methods for their Preparation”, the patent application describes several new cannabinoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities.
Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases.
Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs. This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.”
InMed has initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. He is also the 2007 recipient of the International Association for Cannabinoid Medicines’s prestigious Ester Fride Award for Basic Research, and the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.
Creating a robust patent library of NCEs
The patent application covers technology that allows for the creation of libraries of NCEs that can be tested compared to other drugs in order to select candidates for advancement. The cannabinoid analogs were manufactured in a biosynthetic process using the yeast S. cerevisiae, which is commonly used to produce therapeutic biologicals and vaccines.
Filing this patent application in a number of global jursisdicitions further emphasizes the Company’s commitment towards developing NCEs and enhancing rare cannabinoids R&D opportunities.
Why pursue cannabinoid analogs?
Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:
Targeting certain physiological outcomes in specific diseases;
Improving upon the safety profile of the natural cannabinoids;
Enhancing the ability to integrate with specific delivery technologies; and
Protecting the long-term research investment and commercial opportunities.
Learn more about InMed’s Cannabinoid Analogs:
Novel Patentable Cannabinoid Analogs | InMed Pharmaceuticals
Learn more about InMed’s Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/
Other related developments from around the markets include:
Tilray Inc. reported financial results for the third fiscal quarter. Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters.”
Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, is unveiling its 7ACRES Know the Grow content series, providing Canadians with an inside look at the talent, genetics and grow techniques behind the brand and flower portfolio. The ten-video series is broken into three chapters: the 7ACRES Kincardine Facility, Growing Techniques, and 7ACRES Craft Collective + Future Vision, with each episode diving into a different element of production. The series launched in mid-February and releases a new episode weekly via the 7ACRES.com blog, The Stash, as well as on the 7ACRES Instagram channel, @7acresmj.
Jazz Pharmaceuticals announced that it will report its 2022 first quarter financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 first quarter financial results and provide a business and financial update.
AbbVie Inc. will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of InMed Pharmaceuticals Inc. Click here for disclaimer.
Contact Information:
2818047972
[email protected]
